Physician

John A Banzer, M.D.

According to 2025 Medicare claims, John Banzer, M.D. (NPI: 1912933375) practices cardiology in the Bremerton-Silverdale-Port Orchard, WA market, with the plurality of this provider's patient population coming from Kitsap, WA. This provider's primary affiliated billing organization is FRANCISCAN MEDICAL GROUP (NPI: 1710432612; TIN: 911939739) and primary practice location at 98383-8561. Banzer is affiliated with the CommonSpirit ACO I (ACO ID: A2164) and Jefferson Accountable Care, LLC (ACO ID: A5275), participating under the MSSP model.

Banzer's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,211 traditional Medicare patients, billed 5,496 HCPCS/CPT codes, and received $262,221 in Medicare payments. The top billing code was 93306 (Ultrasound of heart with color-depicted blood flow, rate, direction and valve function). Part D data shows 6,614 prescription claims across 663 beneficiaries totaling $1,250,109 in drug costs, led by Eliquis (Apixaban). 2023 DME data shows 12 claims. Open Payments data shows 101 records totaling $1,998. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $484,241 to $262,221. In contrast, Part D prescription costs have moved from a lower plateau to a higher plateau, from $270,535 to $1,250,109. For DME billing, this smaller-volume category started with an early spike, then settled into a lower baseline, moving from $3,959 to $1,098.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,620	7,548	$484,241
2016	1,822	8,020	$552,184
2017	1,815	8,756	$546,114
2018	1,733	9,143	$549,706
2019	1,693	7,987	$502,719
2020	1,401	6,952	$424,480
2021	1,377	6,010	$325,004
2022	1,333	5,384	$287,696
2023	1,277	4,711	$258,247
2024	1,211	5,496	$262,221

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	474	4,069	$270,535
2016	525	4,567	$290,922
2017	522	4,672	$308,102
2018	529	4,982	$439,523
2019	548	4,959	$557,045
2020	570	5,254	$599,803
2021	548	5,335	$633,416
2022	542	5,303	$722,632
2023	526	5,021	$863,871
2024	663	6,614	$1,250,109

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	27	$3,778
2016	N/R	24	$1,951
2017	N/R	13	$646
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	11	$1,016
2022	N/R	12	$1,065
2023	N/R	12	$1,075
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	349	362	$108
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	793	1,663	$89
78452	Nuclear medicine studies of heart muscle at rest and with stress and spect	138	138	$54
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	603	868	$13
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	116	121	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	463	32,103	$605,031
Xarelto	Rivaroxaban	164	12,360	$226,048
Jardiance	Empagliflozin	115	8,249	$144,272
Repatha Sureclick	Evolocumab	59	3,002	$56,620
Entresto	Sacubitril/Valsartan	29	2,085	$42,884

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	101	$1,998	Boehringer Ingelheim Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for John A. Banzer, M.D.?

Tedicare shows public-source Medicare data for John A. Banzer, M.D. (NPI 1912933375), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does John A. Banzer, M.D. have ACO affiliation data?

John A. Banzer, M.D. is shown with ACO affiliation data for CommonSpirit ACO I (MSSP, ACO ID A2164) and Jefferson Accountable Care, LLC (MSSP, ACO ID A5275).

What billing organization is linked to John A. Banzer, M.D.?

John A. Banzer, M.D. is linked to FRANCISCAN MEDICAL GROUP (billing NPI 1710432612) in the available physician profile data.

Does John A. Banzer, M.D. have Open Payments data?

John A. Banzer, M.D. has 101 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.